Moberg Pharma AB (OSTO:MOB)

kr 10.21 -0.29 (-2.76%) Market Cap: 476.74 Mil Enterprise Value: 171.44 Mil PE Ratio: 0 PB Ratio: 0.53 GF Score: 46/100

Q3 2021 Moberg Pharma AB (publ) Earnings Call Transcript
Nov 09, 2021

kr39.07 (-1.94%)

Earnings
Q2 2021 Moberg Pharma AB (publ) Earnings Call Transcript
Aug 10, 2021

kr35.28 (-1.44%)

Earnings
Q1 2021 Moberg Pharma AB (publ) Earnings Call Transcript
May 11, 2021

kr34.44 (+0.38%)

Earnings
Full Year 2020 Moberg Pharma AB (publ) Earnings Call Transcript
Feb 09, 2021

kr39.94 (-2.28%)

Earnings
Fifth Quarter 2020 Moberg Pharma AB (publ) Earnings Call Transcript
Nov 10, 2020

kr52.49 (+0.27%)

Earnings
Twelve Months 2020 Moberg Pharma AB (publ) Earnings Call Transcript
Aug 11, 2020

kr87.04 (-3.78%)

Earnings
Q2 2020 Moberg Pharma AB (publ) Earnings Call Transcript
Feb 11, 2020

kr99.73 (-4.68%)

Earnings

Q2 2021 Moberg Pharma AB (publ) Earnings Call Transcript

Aug 10, 2021 / 01:00PM GMT

Release Date Price: kr35.28 (-1.44%)

Transcript

Operator

Hello and welcome to the Moberg Pharma Q2 report. (Operator Instructions). And just to remind you, this conference call is being recorded.

Today, I'm pleased to present CEO, Anna Ljung. Please go ahead with your meeting.

Anna Ljung;publ;CEO

Moberg Pharma AB

()-

Thank you and hello. My name is Anna Ljung, and I'm the CEO of Moberg Pharma, and I also have our VP of Finance, Mark Beveridge, with me here today. And we're happy to present the Q2 report that was published earlier this morning. And you can find the report on our website. And there, we also have a PowerPoint presentation, and that's the presentation that I will be using today in this telephone meeting.

So let me start on Page 3 of that presentation. We're a Swedish pharmaceutical company that bases our products on drug delivery of known substances, which reduces time to market and development risk compared to traditional drug development. And our lead program is about MOB-015 against nail fungus, with a global sales potential of $250 million to $500

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.